Resumen de Elevated tissue expression of RANKL and RANK is associated with poorer survival rates in pancreatic cancer patients
Miguel A. Ortega, Laura Jiménez, Oscar Fraile Martínez, Cielo Garcia Montero, Diego De Leon Oliva, María del Val Toledo Lobo, Esther Palacios, Paula Granado, Alfonso Esteban, Luis G. Guijarro, Leonel Pekarek, Ángel Asúnsolo del Barco, Laura López González, María Julia Araceli Buján Varela, Natalio García Honduvilla, Melchor Álvarez de Mon Soto, Miguel A. Saez, Raúl Díaz Pedrero
Pancreatic cancer is a highly lethal malignancy with a growing incidence reported worldwide. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, which is often diagnosed at advanced stages, making its prognosis and medical management difficult. The identification of histopathological biomarkers has allowed a more precise stratification of pancreatic cancer patients, providing additional information about their prognosis and offering possible therapeutic targets to be explored. The prognostic value of the receptor activator of nuclear factor-kappa B (RANK) and its ligand (RANKL) has been evaluated in breast and prostate tumors, however, their usefulness has not been assessed in pancreatic cancer. In the present work, we analyzed the relationship between the protein expression of RANK and RANKL with the survival of 41 patients with pancreatic cancer followed for 60 months, by performing immunohistochemistry and Kaplan-Meier curves. Our results demonstrate a direct association of high expression levels of RANK and RANKL with poorer survival of pancreatic cancer patients in comparison to those with low/medium and null expression levels of both markers.
Further studies should be conducted to explore the carcinogenic role of both components in this type of tumor, as well as additional promising translational uses.
Key words:
